Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harms

Parrish, A.Gray, A.Kredo, T.Maartens, G. Reubenson, G.Cohen, K. De Waal, R.Blockman, M.Nel, J.Rees, H.2020-07-202020-07-202020-04-22https://infospace.mrc.ac.za/handle/11288/595269enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harmsOther